When talking about the pharmaceutical industry, Pfizer Inc. (NYSE: PFE) is bound to come up, even more so with its second-quarter earnings just around the corner. This mega-pharma has been attacking M&A over the past year, winning some decisive battles and losing some as well, but ultimately ending up with a very strong pipeline regardless. This earnings report will showcase what Pfizer has to offer for the second half of 2016, and potentially give some insight into what companies it may be looking to pursue next.
The consensus estimates from Thomson Reuters are $0.62 in earnings per share (EPS) on $13.01 billion in revenue. In the same period of last year, Pfizer reported EPS of $0.56 and $11.85 billion in revenue.
This top pharmaceutical company recently completed its acquisition of Anacor Pharmaceuticals. As mentioned, Pfizer has a very strong pipeline, and being the world’s largest drug manufacturer by sales value supports the Wall Street notion that the company can generate higher long-term revenues through the accelerated growth of its new drugs over the next five years.
When the Treasury Department announced new rules for corporate tax inversions, it effectively scuttled Pfizer’s deal with Allergan. With the deal over, not only are the risk arbitrage funds buying the stock back, but some felt there was as much as a $5 weight on the stock, but top analysts now feel that investors can once again focus on the sum-of-the-parts story, which they feel is compelling, in addition to making accretive purchases like Anacor.
Pfizer has announced that it is starting 20 clinical trials this year, and more soon after, on treatments to conquer cancer, as it also seeks to gain leadership in one of the hottest and most lucrative areas of medicine.
A few analysts weighed in on Pfizer ahead of its earnings report:
- Jefferies reiterated a Buy rating.
- Piper Jaffray has a Buy rating with a $54 price target.
- JPMorgan has a Buy rating with a $40 price target.
- BMO Capital Markets reiterated a Buy rating with a $40 price target.
- Deutsche Bank reiterated a Buy rating.
- Morgan Stanley reiterated a Hold rating with a $36 price target.
- Berenberg Bank initiated coverage with a Hold rating and a $38 price target.
- Merrill Lynch has a Buy rating.
So far in 2016, Pfizer has outperformed the broad markets, with the stock up about 17%. Over the past 52 weeks, the stock is up only about 7%.
Shares of Pfizer were trading up 1% at $37.25 on Monday, with a consensus analyst price target of $ and a 52-week trading range of $28.25 to $37.33.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
